外照射放疗联合酪氨酸激酶抑制剂治疗不可手术切除肝癌疗效的Meta分析-现代医学

外照射放疗联合酪氨酸激酶抑制剂治疗不可手术切除肝癌疗效的Meta分析

单位：武汉科技大学附属天佑医院肿瘤科, 湖北武汉 430000

分类号：R735.7

出版年·卷·期（页码）：2024·52·第二期（192-200）

摘要：

目的：通过Meta分析对比外照射放疗(EBRT)联合酪氨酸激酶抑制剂(TKI)与EBRT或TKI单一治疗在不可手术切除肝癌中的有效性及安全性。方法：对Pubmed、Web of Science、Embase、Cochrane Library、CNKI、万方、维普、SinoMed等中英文数据库进行检索，检索时间截止至2023年4月1日。使用Revman5.4软件进行统计分析。结果：纳入12项研究共922例患者。结果表明，(1) 有效性：联合治疗组的客观缓解率(ORR)、疾病控制率(DCR)高于单一治疗组(OR=2.33，95%CI 1.55~3.52，P＜0.001；OR=5.09，95%CI 2.78~9.32，P＜0.001)；联合治疗组总生存期(OS)、无进展生存期(PFS)均长于单一治疗组(HR=0.67，95%CI 0.57~0.79，P＜0.001；HR=0.58，95%CI 0.48~0.70，P＜0.001)。(2) 安全性：两组间总不良事件(AEs)未见统计学差异(OR=1.11，95%CI 0.93~1.31，P=0.25)，但联合治疗组≥3级AEs发生率更高(OR=1.94，95%CI 1.11~3.38，P=0.02)；对不限级AEs各分类分析发现，除了在胃区不适/腹痛、皮肤反应及白细胞减少方面联合治疗组的发生率更高，其他AEs两组间差异无统计学意义(P＞0.05)；(3) 亚组分析：≥3级AEs在有远处转移及对照组干预措施为TKI时两组间差异无统计学意义，ORR、DCR在无远处转移时两组间差异无统计学意义，余各项与总体人群分析结果一致。结论：EBRT联合TKI较单一治疗可以显著改善不可手术切除肝癌患者的预后，AEs整体可控，但要警惕≥3级AEs的发生，需大样本高质量随机对照试验进一步验证本结论。

Objective: To conduct a Meta-analysis comparing the efficacy and safety of external beam radiation therapy(EBRT) combined with tyrosine kinase inhibitors(TKI) versus EBRT or TKI monotherapy in the treatment of non-resectable live cancer.Methods: Literature were searched in PubMed, Web of Science, Embase, and the Cochrane Library, CNKI, WanFang Data, Vip, and SinoMed until April 1st, 2023. Statistical analyses were conducted using RevMan 5.4 software. Results: Twelve studies with a total of 922 patients were included. The results showed:(1) Effectiveness: the objective remission rate(ORR) and disease control rate(DCR) of the combination therapy group were higher than those of the monotherapy group(OR=2.33, 95%CI 1.55-3.52, P＜0.001; OR=5.09, 95%CI 2.78-9.32, P＜0.001). The overall survival(OS), disease-free survival(DFS), and progression-free survival(PFS) in the combination therapy group were significantly higher than those in the monotherapy group(HR=0.67, 95%CI 0.57-0.79, P＜0.001; HR=0.58, 95%CI 0.48~0.70, P＜0.001). (2) safety: no significant difference was observed in the total number of adverse events(AEs) between the two groups(OR=1.11, 95%CI 0.93-1.31, P=0.25). However, the incidence of grade 3 or higher AEs was higher in the combination therapy group(OR=1.94, 95%CI 1.11-3.38, P=0.02). Analysis of different classifications of AEs without limits revealed that, except for gastric discomfort/abdominal pain, skin reactions, and leukopenia, no significant difference was found between the two groups for other AEs(P＞0.05).(3) Subgroup analysis: no significant difference was observed between the two groups in terms of grade ≥3 AEs in the presence of distant metastasis and the control group when the intervention was TKI. Additionally, no significant difference was found between the two groups for ORR, DCR in the absence of distant metastasis, and the remaining results were consistent with the overall population analysis results.Conclusion: EBRT combined with TKI can significantly improve the prognosis of patients with non-resectable hepatocellular carcinoma compared with monotherapy, and the overall adverse events are controllable. However, we should be alert to the occurrence of grade ≥ 3 AEs, which needs to be further verified by a large-sample, high-quality randomized controlled trial.

参考文献：

[1] LLOVET J M,KELLEY R K,VILLANUEVA A,et al.Hepatocellular carcinoma[J].Nat Rev Dis Primers,2021,7(1):6.
[2] SUNG H,FERLAY J,SIEGEL R L,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[3] VAN LEEUWEN C M,OEI A L,CREZEE J,et al.The alfa and beta of tumours:a review of parameters of the linear-quadratic model,derived from clinical radiotherapy studies[J].Radiat Oncol,2018,13(1):96.
[4] YU W,GU K,YU Z,et al.Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo[J].Cancer Lett,2013,329(1):109-117.
[5] WENG Y S,CHIANG I T,TSAI J J,et al.Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src/STAT3/NF-κB-mediated epithelial-mesenchymal transition and metastasis[J].Int J Radiat Oncol Biol Phys,2023,115(3):719-732.
[6] BRADE A M,NG S,BRIERLEY J,et al.Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2016,94(3):580-587.
[7] CHEN S W,LIN L C,KUO Y C,et al.Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2014,88(5):1041-1047.
[8] American Association for Cancer Research.Radiation+sorafenib extends survival for HCC[J].Cancer Discov,2023,13(4):OF1.
[9] TIERNEY J F,STEWART L A,GHERSI D,et al.Practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials,2007,8:16.
[10] 张天嵩,钟文昭,李博.实用循证医学方法学[M].2版.长沙:中南大学出版社,2014.
[11] 孟丽.放疗联合索拉非尼治疗原发性肝癌伴门静脉癌栓的生存因素分析[D].济南:山东大学,2017.
[12] WADA Y,TAKAMI Y,MATSUSHIMA H,et al.The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced hepatocellular carcinoma:a retrospective study[J].Intern Med,2018,57(10):1345-1353.
[13] YU J I,YOO G S,GOH M J,et al.Safety and efficacy of liver-directed radiotherapy in combination with lenvatinib for hepatocelluar carcinoma with macroscopic tumor thrombosis[J].Front Oncol,2022,12:888755.
[14] CHANG W I,KIM B H,KIM Y J,et al.Role of radiotherapy in Barcelona clinic liver cancer stage C hepatocellular carcinoma treated with sorafenib[J].J Gastroenterol Hepatol,2022,37(2):387-394.
[15] 李小兵,严文辉.立体定向放疗联合索拉非尼治疗复发性肝癌近期疗效分析[J].现代医药卫生,2014,30(16):2456-2458.
[16] 尹小兰,许青.索拉非尼联合立体定向精确放疗治疗肝癌肺转移疗效观察[J].中国临床医学,2016(5)：618-624.
[17] 朱中山,严文辉,李小兵,等.靶向药物索拉非尼联合立体定向放射治疗肝癌肺转移的临床疗效及安全性研究[J].广西医科大学学报,2020,37(6)：1144-1148.
[18] SUN T,HE J,ZHANG S,et al.Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma[J].Oncotarget,2016,7(30):48586-48599.
[19] WANG Q,JI X,SUN J,et al.Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma:a propensity score analysis[J].J Cancer Res Clin Oncol,2023,149(10):7441-7452
[20] QUE J,WU H C,LIN C H,et al.Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis[J].Medicine,2020,99(13):e19660.
[21] LIU C M.Concurrent sorafenib and radiotherapy versus radiotherapy alone for locally advanced hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2020,108(3):e580.
[22] ABULIMITI M,LI Z,WANG H,et al.Combination intensity-modulated radiotherapy and sorafenib improves outcomes in hepatocellular carcinoma with portal vein tumor thrombosis[J].J Oncol,2021,2021:9943683.
[23] CHATTERJEE N,BIVONA T G.Polytherapy and targeted cancer drug resistance[J].Trends Cancer,2019,5(3):170-182.
[24] LI H,WU Z,CHEN J,et al.External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma:a systematic review and Meta-analysis[J].Clin Exp Med,2023,23(5):1537-1549.
[25] YU J I,PARK H C.Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis[J].World J Gastroenterol,2016,22(30):6851-6863.
[26] KISHI N,KANAYAMA N,HIRATA T,et al.Preoperative stereotactic body radiotherapy to portal vein tumour thrombus in hepatocellular carcinoma:clinical and pathological analysis[J].Sci Rep,2020,10(1):4105.
[27] BAI S,WU Y,YAN Y,et al.Evaluation of the efficacy and toxicity of radiotherapy for type III-IV portal vein tumor thrombi[J].Technol Cancer Res Treat,2021,20:1533033821995286.
[28] HIRAOKA A,KUMADA T,KARIYAMA K,et al.Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice:multicenter analysis[J].Hepatol Res,2019,49(1):111-117.
[29] KUZUYA T,ISHIGAMI M,ITO T,et al.Sorafenib vs.lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].Anticancer Res,2020,40(4):2283-2290.
[30] RIM C H,PARK S,SHIN I S,et al.Is the concurrent use of sorafenib and external radiotherapy feasible for advanced hepatocellular carcinoma? A Meta-analysis[J].Cancers(Basel),2021,13(12):2912.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录